Merck ROA 2006-2018 | MRK

Current and historical return on assets (ROA) values for Merck (MRK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Merck ROA for the three months ending September 30, 2018 was 13.42%.
Merck ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $3.35B $85.13B 3.89%
2018-06-30 $1.34B $85.04B 1.53%
2018-03-31 $1.58B $86.04B 1.76%
2017-12-31 $2.39B $87.87B 2.60%
2017-09-30 $2.85B $91.68B 3.03%
2017-06-30 $5.09B $92.80B 5.31%
2017-03-31 $4.35B $96.56B 4.49%
2016-12-31 $3.92B $95.38B 4.03%
2016-09-30 $5.49B $98.34B 5.56%
2016-06-30 $5.13B $96.48B 5.16%
2016-03-31 $4.61B $98.76B 4.57%
2015-12-31 $4.44B $101.68B 4.29%
2015-09-30 $10.78B $101.23B 10.51%
2015-06-30 $9.85B $102.58B 9.59%
2015-03-31 $11.17B $108.35B 11.00%
2014-12-31 $11.92B $98.17B 11.74%
2014-09-30 $5.39B $101.81B 5.21%
2014-06-30 $5.61B $97.86B 5.37%
2014-03-31 $4.52B $108.46B 4.23%
2013-12-31 $4.40B $105.65B 4.14%
2013-09-30 $4.53B $106.42B 4.26%
2013-06-30 $5.14B $106.88B 4.83%
2013-03-31 $6.02B $106.20B 5.68%
2012-12-31 $6.17B $106.13B 5.82%
2012-09-30 $6.76B $106.30B 6.40%
2012-06-30 $6.72B $105.53B 6.36%
2012-03-31 $6.95B $105.51B 6.57%
2011-12-31 $6.26B $105.13B 5.91%
2011-09-30 $4.22B $106.53B 3.98%
2011-06-30 $2.87B $106.20B 2.70%
2011-03-31 $1.60B $105.87B 1.51%
2010-12-31 $0.86B $105.78B 0.80%
2010-09-30 $7.84B $107.84B 7.16%
2010-06-30 $10.92B $106.17B 11.53%
2010-03-31 $11.73B $111.59B 14.56%
2009-12-31 $12.85B $112.31B 20.00%
2009-09-30 $8.03B $48.74B 16.74%
2009-06-30 $5.70B $49.41B 11.89%
2009-03-31 $5.91B $46.54B 12.46%
2008-12-31 $7.79B $47.20B 16.38%
2008-09-30 $4.53B $48.55B 9.46%
2008-06-30 $4.96B $47.46B 10.52%
2008-03-31 $4.87B $47.04B 10.51%
2007-12-31 $3.27B $48.35B 7.21%
2007-09-30 $5.38B $45.70B 12.13%
2007-06-30 $4.80B $44.18B 10.93%
2007-03-31 $4.62B $42.99B 10.57%
2006-12-31 $4.43B $44.57B 10.12%
2006-09-30 $5.08B $43.72B 11.58%
2006-06-30 $5.56B $43.48B 12.67%
2006-03-31 $4.78B $43.42B 10.92%
2005-12-31 $4.63B $44.85B 10.60%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.761B $40.122B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $387.009B 18.15
Pfizer (PFE) United States $255.437B 14.40
Novartis AG (NVS) Switzerland $202.383B 17.29
AbbVie (ABBV) United States $132.837B 11.79
Eli Lilly (LLY) United States $116.324B 20.45
Sanofi (SNY) France $113.065B 14.00
Novo Nordisk (NVO) Denmark $108.639B 17.64
AstraZeneca (AZN) United Kingdom $104.862B 13.02
GlaxoSmithKline (GSK) United Kingdom $101.405B 13.63
Bristol-Myers Squibb (BMY) United States $85.837B 14.14